Cargando…

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

The fibroblast growth factor (FGF)-FGF receptor (FGFR) signaling system plays critical roles in a variety of normal developmental and physiological processes. It is also well documented that dysregulation of FGF-FGFR signaling may have important roles in tumor development and progression. The FGFR4–...

Descripción completa

Detalles Bibliográficos
Autores principales:	French, Dorothy M., Lin, Benjamin C., Wang, Manping, Adams, Camellia, Shek, Theresa, Hötzel, Kathy, Bolon, Brad, Ferrando, Ronald, Blackmore, Craig, Schroeder, Kurt, Rodriguez, Luis A., Hristopoulos, Maria, Venook, Rayna, Ashkenazi, Avi, Desnoyers, Luc R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352934/ https://www.ncbi.nlm.nih.gov/pubmed/22615798 http://dx.doi.org/10.1371/journal.pone.0036713

Ejemplares similares

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Secreted Sulfatases Sulf1 and Sulf2 Have Overlapping yet Essential Roles in Mouse Neonatal Survival
por: Holst, Charles R., et al.
Publicado: (2007)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
por: Englinger, Bernhard, et al.
Publicado: (2018)

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
por: Hall, Terence G., et al.
Publicado: (2016)

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
por: Xiang, Hong, et al.
Publicado: (2021)

Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy
por: Bolon, Brad, et al.
Publicado: (2011)

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019)

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
por: Tian, Meijie, et al.
Publicado: (2023)

Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
por: Wu, Xiao Yu, et al.
Publicado: (2015)

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models
por: Peng, Xia, et al.
Publicado: (2019)

FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways
por: Wu, Ai-Luen, et al.
Publicado: (2011)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models
por: Rosati, Rayna, et al.
Publicado: (2020)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Three interrelated themes in current breast cancer research: gene addiction, phenotypic plasticity, and cancer stem cells
por: Cardiff, Robert D, et al.
Publicado: (2011)

Fgfr1 Inactivation in the Mouse Telencephalon Results in Impaired Maturation of Interneurons Expressing Parvalbumin
por: Smith, Karen Müller, et al.
Publicado: (2014)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study
por: Nan, Hongmei, et al.
Publicado: (2009)

Role of Postnatal Expression of Fgfr1 and Fgfr2 in Testicular Germ Cells on Spermatogenesis and Fertility in Mice
por: Li, Shengqiang, et al.
Publicado: (2014)

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province
por: Jiang, Yongdong, et al.
Publicado: (2015)

Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3
por: Kawane, Tetsuya, et al.
Publicado: (2018)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
por: Lu, Hengyu, et al.
Publicado: (2020)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
por: Sridharan, Vishwajith, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bbi6do4hg7f2koumdc666imblr